Generation of stem cell-derived β-cells from patients with type 1 diabetes
Millman, Jeffrey R.
Van Dervort, Alana
Pagliuca, Felicia W.
MetadataShow full item record
CitationMillman, Jeffrey R., Chunhui Xie, Alana Van Dervort, Mads Gürtler, Felicia W. Pagliuca, and Douglas A. Melton. 2016. “Generation of stem cell-derived β-cells from patients with type 1 diabetes.” Nature Communications 7 (1): 11463. doi:10.1038/ncomms11463. http://dx.doi.org/10.1038/ncomms11463.
AbstractWe recently reported the scalable in vitro production of functional stem cell-derived β-cells (SC-β cells). Here we extend this approach to generate the first SC-β cells from type 1 diabetic patients (T1D). β-cells are destroyed during T1D disease progression, making it difficult to extensively study them in the past. These T1D SC-β cells express β-cell markers, respond to glucose both in vitro and in vivo, prevent alloxan-induced diabetes in mice and respond to anti-diabetic drugs. Furthermore, we use an in vitro disease model to demonstrate the cells respond to different forms of β-cell stress. Using these assays, we find no major differences in T1D SC-β cells compared with SC-β cells derived from non-diabetic patients. These results show that T1D SC-β cells could potentially be used for the treatment of diabetes, drug screening and the study of β-cell biology.
Citable link to this pagehttp://nrs.harvard.edu/urn-3:HUL.InstRepos:27320369